Personalized predictions study for a 29 year old woman who takes Dulera, Cabergoline, Iron Edta, Allegra Allergy - from FDA reports


We analyzed 1,898,061 related reports to generate the predictions. There are 2 types of predictions: symptoms and conditions with supporting statistic provided. You can discuss the predictions with your healthcare provider.

How to use this study: bring a copy to your health teams to ensure drug risks and benefits are fully discussed and understood.

Who is eHealthMe: we are a data analysis company who specializes in health care industry. Our original studies have been referenced on 500+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and EANO. On eHealthMe, you can research drugs and monitor them (see testimonials). If you find eHealthMe useful, please help us to spread the words below or leave us a testimonial.

1,898,061 related reports were analyzed:

Most common symptoms:

Abnormal behavior
  • 5.1% for females aged 29 (±5) who have prolactinoma - females|anemia
Abortion spontaneous
  • 5.26% for females aged 29 (±5) who have prolactinoma - females
Anemia
  • 9.68% for females aged 29 (±5) who have anemia
Asthma
  • 14.67% for females aged 29 (±5) who have asthma|anemia
  • 14.59% for females aged 29 (±5) who have prolactinoma - females|asthma
  • 13.38% for females aged 29 (±5) who have allergy|asthma
Birth control
  • 5.26% for females aged 29 (±5) who have prolactinoma - females
Blood prolactin increased
  • 6.37% for females aged 29 (±5) who have prolactinoma - females|anemia
Breathing difficulty
  • 9.68% for females aged 29 (±5) who have anemia
Chest pain
  • 7.2% for females aged 29 (±5) who have asthma|anemia
  • 7.18% for females aged 29 (±5) who have prolactinoma - females|asthma
  • 6.85% for females aged 29 (±5) who have allergy|asthma
Complications of maternal exposure to therapeutic drugs
  • 7.37% for females aged 29 (±5) who have prolactinoma - females
Constipation
  • 10.19% for females aged 29 (±5) who have prolactinoma - females|anemia
Cough
  • 5.92% for females aged 29 (±5) who have asthma|anemia
  • 5.9% for females aged 29 (±5) who have prolactinoma - females|asthma
  • 5.52% for females aged 29 (±5) who have allergy|asthma
Diplopia
  • 5.1% for females aged 29 (±5) who have prolactinoma - females|anemia
Disease progression
  • 6.32% for females aged 29 (±5) who have prolactinoma - females
Dizziness
  • 19.11% for females aged 29 (±5) who have prolactinoma - females|anemia
  • 7.1% for females aged 29 (±5) who have prolactinoma - females|allergy
  • 5.71% for females aged 29 (±5) who have allergy|anemia
  • 5.32% for females aged 29 (±5) who have prolactinoma - females|asthma
  • 5.21% for females aged 29 (±5) who have asthma|anemia
  • 5.09% for females aged 29 (±5) who have allergy|asthma
Drug effect decreased
  • 7.37% for females aged 29 (±5) who have prolactinoma - females
Drug exposure during pregnancy
  • 5.1% for females aged 29 (±5) who have prolactinoma - females|anemia
Drug ineffective
  • 6.71% for females aged 29 (±5) who have asthma|anemia
  • 6.7% for females aged 29 (±5) who have prolactinoma - females|asthma
  • 6.13% for females aged 29 (±5) who have allergy|asthma
Dyspnea
  • 11.58% for females aged 29 (±5) who have asthma|anemia
  • 11.55% for females aged 29 (±5) who have prolactinoma - females|asthma
  • 10.61% for females aged 29 (±5) who have allergy|asthma
Fatigue
  • 7.21% for females aged 29 (±5) who have allergy|anemia
  • 6.37% for females aged 29 (±5) who have prolactinoma - females|anemia
  • 5.94% for females aged 29 (±5) who have prolactinoma - females|allergy
  • 5.72% for females aged 29 (±5) who have asthma|anemia
  • 5.65% for females aged 29 (±5) who have allergy|asthma
  • 5.54% for females aged 29 (±5) who have prolactinoma - females|asthma
Headache
  • 12.74% for females aged 29 (±5) who have prolactinoma - females|anemia
  • 7.35% for females aged 29 (±5) who have prolactinoma - females|allergy
  • 6.94% for females aged 29 (±5) who have allergy|anemia
  • 6.01% for females aged 29 (±5) who have prolactinoma - females|asthma
  • 5.97% for females aged 29 (±5) who have asthma|anemia
  • 5.87% for females aged 29 (±5) who have allergy|asthma
Heart palpitations
  • 5.1% for females aged 29 (±5) who have prolactinoma - females|anemia
Insomnia exacerbated
  • 11.29% for females aged 29 (±5) who have anemia
Maternal exposure during pregnancy
  • 7.37% for females aged 29 (±5) who have prolactinoma - females
Mucosal dryness
  • 8.28% for females aged 29 (±5) who have prolactinoma - females|anemia
Nausea
  • 6.15% for females aged 29 (±5) who take dulera
  • 6.15% for females aged 29 (±5) who take cabergoline
  • 6.15% for females aged 29 (±5) who take iron edta
  • 6.15% for females aged 29 (±5) who take allegra allergy
  • 5.88% for females aged 29 (±5) who have asthma|anemia
  • 5.87% for females aged 29 (±5) who have allergy|asthma
  • 5.83% for females aged 29 (±5) who have prolactinoma - females|asthma
  • 5.44% for females aged 29 (±5) who have allergy|anemia
  • 5.42% for females aged 29 (±5) who have prolactinoma - females|allergy
Nausea and vomiting
  • 10.19% for females aged 29 (±5) who have prolactinoma - females|anemia
Oedema
  • 5.1% for females aged 29 (±5) who have prolactinoma - females|anemia
Orthostatic hypotension
  • 8.28% for females aged 29 (±5) who have prolactinoma - females|anemia
Pain
  • 7.95% for females aged 29 (±5) who have asthma|anemia
  • 7.88% for females aged 29 (±5) who have prolactinoma - females|asthma
  • 7.31% for females aged 29 (±5) who have allergy|asthma
Psychomotor hyperactivity
  • 8.92% for females aged 29 (±5) who have prolactinoma - females|anemia
Stress and anxiety
  • 6.4% for females aged 29 (±5) who have asthma|anemia
  • 6.36% for females aged 29 (±5) who have prolactinoma - females|asthma
  • 6.23% for females aged 29 (±5) who have allergy|asthma
Weight increased
  • 6.37% for females aged 29 (±5) who have prolactinoma - females|anemia

Most common co-existing conditions:

Attention deficit hyperactivity disorder
  • 9.52% for females aged 29 (±5) who have allergy|anemia
  • 8.39% for females aged 29 (±5) who have prolactinoma - females|allergy
Birth control
  • 14.15% for females aged 29 (±5) who have allergy|anemia
  • 14.0% for females aged 29 (±5) who take dulera
  • 14.0% for females aged 29 (±5) who take cabergoline
  • 14.0% for females aged 29 (±5) who take iron edta
  • 14.0% for females aged 29 (±5) who take allegra allergy
  • 13.42% for females aged 29 (±5) who have prolactinoma - females|allergy
  • 11.89% for females aged 29 (±5) who have allergy|asthma
  • 11.49% for females aged 29 (±5) who have asthma|anemia
  • 11.43% for females aged 29 (±5) who have prolactinoma - females|asthma
Constipation
  • 5.73% for females aged 29 (±5) who have prolactinoma - females|anemia
Depression
  • 17.2% for females aged 29 (±5) who have prolactinoma - females|anemia
  • 16.05% for females aged 29 (±5) who have allergy|anemia
  • 13.29% for females aged 29 (±5) who have prolactinoma - females|allergy
  • 8.31% for females aged 29 (±5) who have allergy|asthma
  • 7.97% for females aged 29 (±5) who have asthma|anemia
  • 7.57% for females aged 29 (±5) who have prolactinoma - females|asthma
Fibromyalgia
  • 8.06% for females aged 29 (±5) who have anemia
Fluid imbalance
  • 11.29% for females aged 29 (±5) who have anemia
Gastroesophageal reflux disease
  • 12.38% for females aged 29 (±5) who have allergy|anemia
  • 11.23% for females aged 29 (±5) who have prolactinoma - females|allergy
  • 6.3% for females aged 29 (±5) who have allergy|asthma
  • 5.81% for females aged 29 (±5) who have asthma|anemia
  • 5.73% for females aged 29 (±5) who have prolactinoma - females|anemia
  • 5.61% for females aged 29 (±5) who have prolactinoma - females|asthma
Generalized anxiety disorder
  • 5.71% for females aged 29 (±5) who have allergy|anemia
High blood pressure
  • 5.03% for females aged 29 (±5) who have allergy|anemia
Hypersensitivity
  • 6.6% for females aged 29 (±5) who have asthma|anemia
  • 6.56% for females aged 29 (±5) who have prolactinoma - females|asthma
  • 5.99% for females aged 29 (±5) who have allergy|asthma
Hypothyroidism
  • 5.14% for females aged 29 (±5) who have allergy
Insomnia
  • 9.55% for females aged 29 (±5) who have prolactinoma - females|anemia
  • 7.62% for females aged 29 (±5) who have allergy|anemia
  • 5.81% for females aged 29 (±5) who have prolactinoma - females|allergy
Migraine
  • 6.26% for females aged 29 (±5) who have allergy|anemia
  • 5.68% for females aged 29 (±5) who have prolactinoma - females|allergy
Multiple sclerosis
  • 7.42% for females aged 29 (±5) who take dulera
  • 7.42% for females aged 29 (±5) who take cabergoline
  • 7.42% for females aged 29 (±5) who take iron edta
  • 7.42% for females aged 29 (±5) who take allegra allergy
Pain
  • 5.85% for females aged 29 (±5) who have allergy|anemia
  • 5.76% for females aged 29 (±5) who have asthma|anemia
  • 5.73% for females aged 29 (±5) who have prolactinoma - females|anemia
  • 5.56% for females aged 29 (±5) who have prolactinoma - females|asthma
  • 5.47% for females aged 29 (±5) who have allergy|asthma
Post-traumatic epilepsy
  • 5.1% for females aged 29 (±5) who have prolactinoma - females|anemia
Respiratory tract infection
  • 8.28% for females aged 29 (±5) who have prolactinoma - females|anemia
Stress and anxiety
  • 11.29% for females aged 29 (±5) who have allergy|anemia
  • 10.45% for females aged 29 (±5) who have prolactinoma - females|allergy
  • 5.62% for females aged 29 (±5) who have allergy|asthma
  • 5.1% for females aged 29 (±5) who have prolactinoma - females|anemia
  • 5.04% for females aged 29 (±5) who have asthma|anemia
Vulvovaginal mycotic infection
  • 6.37% for females aged 29 (±5) who have prolactinoma - females|anemia

Recent updates

Recent general studies
Recent personal studies

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the ePatient.care site and its content is at your own risk.

Submit your testimonial

  • Please fill in your Testimonial.
  • Please enter a minimum of 10 characters for your Testimonial.
  • Please fill in your Name.

Please wait...

{progressItem}

Thank you!